PCI Biotech Holding ASA (LTS:0JGL) Other Operating Expense: kr0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PCI Biotech Holding ASA Other Operating Expense?

PCI Biotech Holding ASA LTS:0JGL Other Operating Expense is kr0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's Other Operating Expense for the six months ended in Dec. 2025 was kr0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.00 Mil.

PCI Biotech Holding ASA's annual Other Operating Expense declined from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr0.00 Mil) and declined from Dec. 2024 (kr0.00 Mil) to Dec. 2025 (kr-0.00 Mil).

PCI Biotech Holding ASA Other Operating Expense Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Other Operating Expense Chart

PCI Biotech Holding ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

PCI Biotech Holding ASA Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial - 0.00 0.00 0.00 0.00

PCI Biotech Holding ASA Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of kr0.00 Mil mean?
PCI Biotech Holding ASA (LTS:0JGL) has a Other Operating Expense of kr0.00 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Other Operating Expense too high?
PCI Biotech Holding ASA's current Other Operating Expense is kr0.00 Mil.
How does PCI Biotech Holding ASA's Other Operating Expense compare to VRTX and REGN?
PCI Biotech Holding ASA's Other Operating Expense of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Other Operating Expense is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current Other Operating Expense of kr0.00 Mil. The current Other Operating Expense is kr0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current Other Operating Expense is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a Norwegian clinical-stage biopharmaceutical company developing cancer therapies based on its photochemical internalization (PCI) technology platform, which uses light to trigger the release of compounds trapped inside cellular compartments. The company applies PCI across three programs: fimaCHEM, which aims to enhance chemotherapeutic drugs for localized cancer treatment; fimaVACC, which seeks to induce T-cell responses for therapeutic cancer vaccination; and fimaNAc, which targets delivery of nucleic acid therapeutics. Its lead product candidate is fimaporfin (Amphinex), a photosensitizer used to unlock intracellular compartments. The company operates as a single research and development segment, generating no product revenue and relying on equity financing and partnerships to fund its preclinical and clinical development activities. Its activities are based in Norway, with development efforts directed toward international oncology and immunotherapy markets.